OTC Pediatric Healthcare Market

Market Overview

OTC pediatric healthcare market is projected to witness sluggish growth at CAGR of 2.1% during 2017-2022. Over-The-Counter (OTC) medicines can be purchased without doctor’s prescription. OTC drugs are used to treat minor ailments and are usually consumed on basis of self-diagnosis.

These drugs are available at pharmacies, small convenience stores as well as at supermarkets. OTC medication is usually not recommended, especially in case of children as they are more likely to have adverse drug reactions than adults. The adverse effects wrong medicine or overdosage can result in an allergic reaction and other side-effects.

OTC medicines have a low risk if used properly by adults, but these drugs pose greater risks for children, especially in the case of first-time medication or if a child is suffering from some other health conditions. According to the U.S. Food and Drug Administration (FDA), OTC medicines to treat cold and cough for children under 2 years of age should be avoided as these medicines can cause serious or life-threatening side-effects.

FDA also warns against the use of codeine products to treat cold and cough in children less than 12 years of age as it can result in serious breathing problems. OTC medicines including aspirin are also not recommended for children as aspirin can lead to Reye’s syndrome in children, which is a rear but potentially serious illness.

According to the latest report by Fact.MR, the global market for OTC pediatric healthcare is anticipated to reach close to US$ 10,000 million revenue by 2022 end. The market is expected to experience sluggish growth during the forecast period, 2017 to 2022. Increasing risk of serious side-effects due to OTC medicines based on self-care decision is restricting the parents from choosing OTC drugs for children, thus leading to the decline in OTC pediatric healthcare.

Dermatology- Top-Selling Product

OTC pediatric medicines that fall under dermatology are projected to remain top-selling products in the global OTC pediatric healthcare market between 2017 and 2022. Sale of Dermatology OTC pediatric drugs is expected to bring in nearly US$ 3,500 million revenues towards the end of 2022. Meanwhile, ENT OTC pediatric medicines are anticipated to account for lowest revenue shares. OTC cold and cough medicines are not recommended for children because of the risk of serious side-effects and high chances of developing breathing problems.

High Sales through Drug Stores/ Pharmacies

Accounting for nearly one-third of revenue share in the OTC pediatric healthcare, drug stores/ Pharmacies emerge as one of the most lucrative sales channels. Towards the end of 2022, drug stores/ pharmacies are projected to reach close to US$ 3,200 million revenues. Although, global sales of OTC pediatric medicines through hospital pharmacies is projected to create an incremental opportunity of over US$ 300 million during 2017-2022.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global OTC pediatric healthcare market through 2022, which include

• Procter & Gamble
• Johnson & Johnson
• GlaxoSmithKline Plc
• Abbott Laboratories
• Amway Corporation
• Bayer Aktiengesellschaft
• Sanofi
• Pfizer Inc.
• Reckitt Benckiser Group plc
• Church & Dwight Co. Inc.

Market Taxonomy

Product Type	Gastro Intestinal Dermatology ENT Nutrition/Vitamins Other Products
Sales Channel	Drug store/ Pharmacy Hospital Pharmacies Modern Trade Convenience Store Online Retailers Other Channel
Region	North America Latin America Europe Japan APEJ MEA

Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)